FUSION PROTEIN COMPRISING ANTI-TAA ANTIBODY, ANTI-PD-L1 ANTIBODY, AND IL-2, AND USES THEREOF

WIPO Patent Application WO/2021/153979

A1

The present invention relates to a fusion protein comprising an anti-TAA antibody, an anti-PD-L1 antibody, and IL-2, and uses thereof, wherein the fusion protein: has excellent binding affinity to CEA, which is a tumor-associated antigen, and to PD-L1, which is an immune gateway; can specifically bind to tumor cells expressing CEA and/or PD-L1; can induce proliferation of T cells and NK cells and activate immune cells; and can exhibit excellent anticancer effects when administered to cancer-induced mice, and thus can be advantageously used in the treatment of cancer diseases.

WO2001064024	MULTIPLE GENE EXPRESSION FOR ENGINEERING NOVEL PATHWAYS AND HYPEREXPRESSION OF FOREIGN PROTEINS IN PLANTS
JP6722264	Antibodies that neutralize RSV, MPV and PVM and their use
WO/1996/000282	EXPRESSION CASSETTES USEFUL IN CONSTRUCTION OF INTEGRATIVE AND REPLICATIVE EXPRESSION VECTORS FOR STREPTOMYCES

SUNG YOUNG CHUL (KR)
YOUN JIN WON (KR)
SHIN EUN JU (KR)

PCT/KR2021/001054

August 05, 2021

January 27, 2021

Click for automatic bibliography generation  

GENEXINE INC (KR)

C12N15/63; A61K38/00; A61P35/00; C07K14/55; C07K16/28; C07K16/30

WO2019147837A2

2019-08-01

US20180318417A1	2018-11-08
KR20190032355A	2019-03-27
KR20180119135A	2018-11-01
KR20170032461A	2017-03-22

ERUUM & LEEON INTELLECTUAL PROPERTY LAW FIRM (KR)

View/Download PDF      PDF Help

Previous Patent: COMPOSITION FOR PRODUCING CAT LITTER USING COFFEE GROUNDS, CAT LITTER, AND METHOD FOR PRODUCING CAT ...

Next Patent: PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 A...